Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Cash & Equivalents data on record, last reported at $210.6 million in Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 208.56% to $210.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $210.6 million, a 208.56% increase, with the full-year FY2025 number at $210.6 million, up 208.56% from a year prior.
  • Cash & Equivalents reached $210.6 million in Q4 2025 per NBP's latest filing, down from $228.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for NBP hit a ceiling of $737.0 million in Q2 2021 and a floor of $53.6 million in Q1 2025.
  • A 5-year average of $315.8 million and a median of $297.4 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 233.79% in 2021, then plummeted 77.05% in 2024.
  • Tracing NBP's Cash & Equivalents over 5 years: stood at $551.1 million in 2021, then decreased by 18.0% to $451.9 million in 2022, then crashed by 34.18% to $297.4 million in 2023, then tumbled by 77.05% to $68.3 million in 2024, then surged by 208.56% to $210.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for NBP at $210.6 million in Q4 2025, $228.1 million in Q3 2025, and $165.4 million in Q2 2025.